Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
24 January 2021 | Story Lacea Loader
Ivermectin

FARMOVS, a wholly owned clinical research company of the University of the Free State (UFS), together with several medical and scientific experts at the university, is currently in the process of preparing a clinical trial protocol to determine the efficacy of Ivermectin for COVID-19 in a randomised, controlled study according to the requirements of the legal professions, in order to submit it for approval to the relevant national regulatory authority.

FARMOVS is a South African specialty full-service clinical research organisation conducting ICH-GCP-compliant Phase I to IV clinical trials. FARMOVS’ competitive advantage is its wealth of bioequivalence and Phase I experience and expertise, patient recruitment success, and a clinical research facility with the only onsite ISO (International Organization for Standardization) and GLP (Good Laboratory Practice) certified bioanalytical laboratory on the African continent.

By participating in the preparation of the clinical trial protocol, FARMOVS and the UFS remain supportive of and committed to contributing to the development of treatments and treatment strategies to battle the COVID-19 pandemic. Should the clinical trial protocol be approved by the relevant national regulatory authority, the UFS will be the first university in South Africa to attempt such a study.

The university management is aware of a WhatsApp voice clip being circulated, in which reference is made to a particular meeting, and mention is made of the role the institution is playing in establishing the efficacy of Ivermectin for COVID-19. The voice clip is premature and was shared with a small group, from where it went viral. The voice clip is also not factual – specifically regarding the university and its alleged opinion pertaining to the usage and need for scientific investigation into the matter.  

The UFS is committed to rigorous science and evidence-based research, and both FARMOVS and the university fully support the published opinions and guidelines of the South African Health Products Regulatory Authority (SAHPRA) and the scientific advisory boards established by the scientific community, as well as the stance of the South African government on Ivermectin for COVID-19.

Released by:
Lacea Loader (Director: Communication and Marketing)
Telephone: +27 51 401 2584 | +27 83 645 2454
Email: news@ufs.ac.za | loaderl@ufs.ac.za

News Archive

Inaugural lecture focuses on spinal surgery
2005-07-25

  
 
Prof John Shipley, from the Department of Orthopaedics at the University of the Free State (UFS), will deliver his inaugural lecture on Wednesday 27 July 2005 at 19:00 in the CR Swart Auditorium on campus.  

The topic of the lecture is The intervertebral disc:  Past, present and future. 

Prof Shipley studied medicine at the University of Cape Town.  He specialised in Orthopaedic Surgery at the UFS, qualifying in 1981.  He remained in the Department as a Consultant and was appointed Associate Professor in 1992.  Following a period of private practice in Bloemfontein, he was appointed Head of the Department of Orthopaedics in 2004.

He has specialised in spinal surgery and was chairman of the SA Spine Society in 1993 and 1998.  He serves on the Executive Committee of the SA Orthopaedic Association and the College of Surgeons of SA.  He was the South African ABC Traveling Fellow to North America in 1986 and has been the main author of two international and eight local publications and two textbook chapters.  He has delivered 28 presentations at congresses.

For any enquiries, please contact Ms Joan Nel at (051) 401-9301.

Media release

Issued by:  Lacea Loader
   Media Representative
   Tel:  (051) 401-2584
   Cell:  083 645 2454
   E-mail:  loaderl.stg@mail.uovs.ac.za

25 July 2005
 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept